Ablynx is looking for new partners to take its rheumatoid arthritis drug vobarilizumab into phase 3 development, after AbbVie turned down an option to license the drug. AbbVie has already paid the ...

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on ...

Kidney transplantation from donors with HIV appeared to be noninferior to donors without HIV in terms of safety for ...

Xaira Therapeutics today announced the appointment of Dr. Debbie Law and Julia Tran to its C-suite. Law will serve as chief ...

Thus, Ghent, Belgium–based Ablynx is developing a class of antibody fragment based on a single variable domain, a hinge region and two constant domains (CH2 and CH3) derived from llama antibodies.